FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
BioSpace2h
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Hosted on MSN19m
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Managed Healthcare Executive10h
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
WAMC17h
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
pharmaphorum3d
J&J builds case for antidepressant Spravato with head-to-head trial
Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.
pharmaphorum4d
J&J’s Spravato for depression ‘should be much cheaper’
Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...